Anaphylaxis to anakinra in a pediatric patient with systemic juvenile idiopathic arthritis successfully treated with canakinumab: a case-based review.
Clin Rheumatol
; 34(10): 1821-4, 2015 Oct.
Article
in En
| MEDLINE
| ID: mdl-25697878
ABSTRACT
We present the case of a 2-year-old boy with a history of necrotizing enterocolitis (NEC) with ileostomy diagnosed with systemic juvenile idiopathic arthritis (sJIA) at 10 months of age controlled on anti-interleukin-1 (anti-IL-1) therapy (anakinra). At 17 months of age, ileostomy reversal and bowel re-anastomosis was scheduled with anakinra discontinued 3 days prior to the surgery and steroids initiated in its place. Ten days postoperatively, anakinra was re-started for signs of sJIA flare. Three months later, he developed persistent peripheral eosinophilia and subsequent anaphylactic reaction 6 months postoperatively. The patient safely tolerated an alternative anti-IL-1 agent (canakinumab). Anaphylaxis to anakinra has not been previously reported in the pediatric literature. This case highlights an important issue in a pediatric patient with sJIA safety of an alternate anti-IL-1 agent, following development of allergy to one initial agent.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Arthritis, Juvenile
/
Antirheumatic Agents
/
Interleukin 1 Receptor Antagonist Protein
/
Anaphylaxis
/
Antibodies, Monoclonal
Type of study:
Etiology_studies
Limits:
Child, preschool
/
Humans
/
Male
Language:
En
Journal:
Clin Rheumatol
Year:
2015
Type:
Article
Affiliation country:
United States